We are live on ! Find out more
NMC

NEA Management Company Portfolio holdings

AUM $1.76B
1-Year Est. Return 223.33%
This Fund
S&P 500
This Quarter Est. Return
+2.84%
1 Year Est. Return
+223.33%
3 Year Est. Return
+769.45%
5 Year Est. Return
+668.45%
10 Year Est. Return
+14,843.34%
AUM
$1.43B
AUM Growth
-$499M
Cap. Flow
-$449M
Cap. Flow %
-31.45%
Top 10 Hldgs %
64.34%
Holding
48
New
3
Increased
3
Reduced
1
Closed
4

Top Buys

Rank Stock Value
1
PHAS
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
+$81.4M
2
TRVI icon
Trevi Therapeutics
TRVI
+$38.1M
3
GNCA
Genocea Biosciences, Inc.
GNCA
+$14.9M
4
AVEO
AVEO Pharmaceuticals, Inc.
AVEO
+$3.72M
5
XENE icon
Xenon Pharmaceuticals
XENE
+$1.75M

Top Sells

Rank Stock Value
1
ESTC icon
Elastic
ESTC
+$444M
2
CMTA
Clementia Pharmaceuticals Inc.
CMTA
+$70.7M
3
EPZM
Epizyme, Inc
EPZM
+$32.2M
4
NITE
Nightstar Therapeutics plc American Depositary Shares
NITE
+$30.8M
5
ARQL
Arqule Inc
ARQL
+$12.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.45%
2 Industrials 1.15%
3 Technology 0.87%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SBBP
26
DELISTED
Strongbridge Biopharma plc.
SBBP
$13M 0.91%
4,141,308
– –
DZSI
27
DELISTED
DZS Inc. Common Stock
DZSI
$12.4M 0.87%
956,255
– –
CSBR icon
28
Champions Oncology
CSBR
$74.5M
$12.2M 0.86%
1,562,500
– –
SURF
29
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$9.35M 0.65%
3,315,149
– –
RIGL icon
30
Rigel Pharmaceuticals
RIGL
$681M
$8.46M 0.59%
324,315
– –
VRNA
31
DELISTED
Verona Pharma
VRNA
$6.22M 0.44%
1,219,674
– –
KA
32
DELISTED
Kineta, Inc. Common Stock
KA
$5.42M 0.38%
39,691
– –
XFOR icon
33
X4 Pharmaceuticals
XFOR
$375M
$5M 0.35%
11,111
– –
PHXM
34
DELISTED
PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM
$4.47M 0.31%
62,500
– –
TRVN
35
DELISTED
Trevena, Inc.
TRVN
$3.93M 0.28%
6,099
– –
CTIC
36
DELISTED
CTI BioPharma Corp. (DE) Common Stock
CTIC
$3.22M 0.23%
3,750,000
– –
RGLS
37
DELISTED
Regulus Therapeutics
RGLS
$2.57M 0.18%
205,246
+113,671
+124% +$1.31M
TCON
38
DELISTED
TRACON Pharmaceuticals, Inc. Common Stock
TCON
$2.36M 0.17%
17,336
– –
ELGX
39
DELISTED
Endologix Inc
ELGX
$1.8M 0.13%
249,021
– –
XENE icon
40
Xenon Pharmaceuticals
XENE
$6.06B
$1.8M 0.13%
+182,754
New +$1.75M
VIRX
41
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$943K 0.07%
37,094
– –
AKTX
42
Akari Therapeutics
AKTX
$13.8M
$913K 0.06%
565
– –
TRIL
43
DELISTED
Trillium Therapeutics Inc.
TRIL
$691K 0.05%
2,100,000
– –
AKAO
44
DELISTED
Achaogen Inc
AKAO
$99K 0.01%
5,215,128
– –
ESTC icon
45
Elastic
ESTC
$6.84B
– –
-5,562,153
Closed -$444M
ARQL
46
DELISTED
Arqule Inc
ARQL
– –
-2,520,316
Closed -$12.1M
NITE
47
DELISTED
Nightstar Therapeutics plc American Depositary Shares
NITE
– –
-1,214,285
Closed -$30.8M
CMTA
48
DELISTED
Clementia Pharmaceuticals Inc.
CMTA
– –
-2,707,734
Closed -$70.7M
1
2

Similar funds

NM
NWI Management New York $1.76B AUM 45.08% 1-Year Est. Return
SLF
Sun Life Financial Toronto, Ontario, Canada $1.76B AUM 19.57% 1-Year Est. Return
CCIA
Campbell & Co Investment Adviser Baltimore, Maryland $1.76B AUM 13.06% 1-Year Est. Return
SW
Simplicity Wealth Summit, New Jersey $1.76B AUM 20.49% 1-Year Est. Return
CGH
Contrarius Group Holdings Hamilton, Bermuda $1.77B AUM 83.15% 1-Year Est. Return
PWP
Principle Wealth Partners Madison, Connecticut $1.75B AUM 21.63% 1-Year Est. Return
CIP
CAS Investment Partners Westport, Connecticut $1.75B AUM 41.95% 1-Year Est. Return
GD
Grandfield & Dodd New York $1.77B AUM 23.43% 1-Year Est. Return

NEA Management Company's Q2 2019 Portfolio in Review

As of Q2 2019, NEA Management Company held 48 positions worth $1.43B, down 26% from $1.93B the previous quarter. Its ten largest holdings account for 64% of the portfolio.

NEA Management Company withdrew a net $449M in Q2 2019, closing 4 positions and reducing 1 holding. Its most notable exit was Elastic, an estimated $444M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 73% a quarter earlier, followed by Industrials and Technology.

Against the trend, NEA Management Company opened a new position in PhaseBio Pharmaceuticals, Inc. Common Stock worth $87.2M.

  • NEA Management Company's largest Q2 2019 buy was PhaseBio Pharmaceuticals, Inc. Common Stock: 6,643,704 shares worth $87.2M.
  • NEA Management Company added most to Genocea Biosciences, Inc. in Q2 2019, an estimated $14.9M increase.
  • NEA Management Company's biggest Q2 2019 reduction was Epizyme, Inc, cutting an estimated $32.2M.
  • NEA Management Company fully exited Elastic in Q2 2019, selling an estimated $444M.
  • NEA Management Company's ten largest holdings make up 64% of its $1.43B portfolio in Q2 2019.
  • NEA Management Company opened 3 new positions and closed 4 in Q2 2019.
  • NEA Management Company's portfolio value fell 26% quarter-over-quarter to $1.43B.

Based on NEA Management Company's 13F filing for Q2 2019, filed 7 Aug 2019.